300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Burkina Faso
LATAM
Brazil
Africa
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
W. Lowry Caudill, Angel Investor

W. Lowry Caudill

Angel Investor

Durham, United States

W. Lowry Caudill is a Series A investor in Durham focused on Biopharma and Therapeutics. Lowry Caudill is the retired, worldwide President of Pharmaceutical Development for Cardinal Health. The Pharmaceutical Development business unit provided complete development services for the pharmaceutical industry. Caudill led over 1400 employees in nine sites including RTP, San Diego, Somerset NJ, Philadelphia, Manchester UK and Schorndorf GER.In April 2002, Cardinal Health acquired Magellan Laboratories Incorporated, a pharmaceutical development company that Caudill and Alfred Childers co-founded in 1991. Under their leadership Magellan grew to 600 people with 500 employees in RTP and 100 employees in San Diego. Magellan was recognized as one of the fastest growing, privately held companies in the Research Triangle area and received numerous regional and national awards for growth and entrepreneurial development. Magellan was awarded the Triangle Business Journal’s Fast 50 award for nine years and was in the Top 10 for six of the nine years. In 1998, Drs. Caudill and Childers were named Entrepreneur of the Year for North and South Carolina by Ernst and Young, the Kauffman Foundation, USA TODAY, and NASDAQ and were Finalists for the 1998 National Entrepreneur Of The Year. They received two awards from the North Carolina Council for Entrepreneurial Development (CED), the 2002 Entrepreneurial Excellence Award and the 2002 Deal of the Year Award.Caudill received his B.S. degree in Chemistry at the University of North Carolina at Chapel Hill with undergraduate research under the direction of Professor Royce Murray. In 1983, Caudill received his doctorate in Analytical Chemistry from Indiana University under the direction of Professor R. Mark Wightman. His dissertation was titled Development and Application of High Performance Liquid Chromatography with Electrochemical Detection. Upon graduation, he became a research scientist at Baxter-Travenol. In addition to general fanatical activities, he managed a formulation development laboratory, which was responsible for the formulation, development and stability evaluation of frozen premixed parenteral products. In 1987, he joined the Glaxo Research Institute where he played a major role in the establishment of the Analytical Chemistry Department in RTP. Currently marketed product lines which his groups helped develop include Zantac, Imitrex, Zofran, Zinacef, and Ventolin.Caudill is an active entrepreneur and supporter of entrepreneurial endeavors. He serves on the Advisory Board of Southern Capitol Ventures, serves on the Life Sciences Advisory Board of the Aurora Funds and is a member of the Tri-State Investment Group. He is an investor in and member of the Board of Directors of Liquidia Technologies Incorporated. He is a former board member of and investor in Knowledge Vector, Piedmont Pharmaceuticals and Aldagen Inc.Caudill is Chair of the Board of Trustees at the University of North Carolina at Chapel Hill and of the University’s Innovation Circle. He was a Steering Committee member of the $2.4 billion Carolina First Campaign and is chair of the Private Fundraising Steering Committee for the UNC-CH Physical Science Complex. He is an Adjunct Professor of Chemistry at the UNC-CH and a member of the UNC-CH Chemistry Department External Advisory Board. He is a member of the Advisory Working Group for the UNC-CH Entrepreneurship Minor and is chair of the Private Fundraising Campaign for the Entrepreneurship Minor. He and Professor Holden Thorp created and taught the first Scientific Ventures course for the UNC-CH Entrepreneurship Minor. In the spring semesters of 2008 and 2009, he co-taught the Scientific Ventures course with Professor Joe DeSimone. He co-taught the Introduction to Entrepreneurship course in 2007 and 2008 for the Entrepreneurship Minor. He is a member of the Executive Board of The Educational Foundation at UNC-CH. In 2008, he received the Distinguished Alumnus Award from UNC-CH.He is an active member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists (AAPS).Dr. Caudill has chaired numerous boards at Aldersgate United Methodist Church in Durham, NC and presently serves as chair of the Administrative Board and the Building Committee. He was a Team Leader for the Aldersgate 2008 Jamaica Mission Team. Dr. Caudill, and his wife, Suzi, and children reside in Durham. His oldest daughter is a senior at UNC-CH and his son is a sophomore at UNC-CH.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries W. Lowry Caudill invests in

BiopharmaTherapeuticsBiotechnologyNanotechnology

Stages W. Lowry Caudill invests in

Series A

Countries W. Lowry Caudill invests in

United States

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biopharma 1 (100%)
  • Therapeutics 1 (100%)
  • Biotechnology 1 (100%)
  • Nanotechnology 1 (100%)

Investments

CompanyDescriptionRoundLinks
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. $6M / Series A / Jun 14, 2006

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Burkina Faso
LATAM
Brazil
Africa
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does W. Lowry Caudill invest in?

W. Lowry Caudill invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact W. Lowry Caudill?

Public channels for W. Lowry Caudill include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did W. Lowry Caudill last invest?

The most recent investment recorded for W. Lowry Caudill closed in Jun 2006. Shizune tracks 1 investment in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
W. Lowry Caudill W. Lowry Caudill Find email